Effect of heparin sodium on postoperative inflammation after adult cataract surgery

To evaluate the effect of use of ringer lactate solution supplemented with heparin sodium in patients undergoing cataract surgery.In a prospective, double-blind, interventional study, 200 patients were included and were randomized to undergo cataract surgery using ringer lactate solution with or without 10 IU/ml heparin. All patients underwent phacoemulsification with hydrophobic acrylic foldable intraocular lens (IOL) implantation. The severity of anterior chamber inflammation and amount of pigment deposition of IOL was assessed by slit lamp biomicroscopy on day 1, 7, 28 and after 8 weeks postoperatively. Mean age in treatment and control group was 63.0± 11.5 years and 65.1±12.7 years respectively. A significant reduction in the severity of inflammatory cellular activity (p=0.001), flare (p=0.001) and pigment deposition on IOL (p=0.001) was noted on day 1 in the heparin treated group compared to the control group. However, no significant difference was observed in the amount of inflammatory activity as well as IOL pigment deposition beyond 1 week postoperatively. The inflammatory activity resolved almost completely in both the groups by the end of 8 weeks postoperatively. : Our study showed the beneficial effect of addition of heparin to irrigating solution during cataract surgery. Heparin treated eyes demonstrated a reduction in the early postoperative inflammation and IOL pigment deposition. The anti-inflammatory effect was observed in the early postoperative period.

Experience of applying a multi-component gel based on troxerutin, heparin sodium and dexpanthenol in the rehabilitation of patients after cosmetic procedures

The article reports an up-to-date classification of complications of cosmetic procedures and two clinical cases where multicomponent gel based on troxerutin, heparin sodium and depanthenol was used to rehabilitate patients after cosmetic procedures complicated by ecchymosis, hematomas and edema. In the first case a 30-year-old patient had a procedure to give greater volume to her lips and to correct their asymmetry with hyaluronic acid filler. The procedure was complicated by the formation of hematomas and edema. To minimize the edema and hematomas and to avoid the risk of infection the patient was prescribed 0.05% aqueous solution of chlorhexidine bi-gluconate once per day and taking of multicomponent gel based on troxerutin, heparin sodium and depanthenol two times per day for seven days. By the fifth day there was observed a significant decrease in edema of the lip area and almost complete resorption of hematomas. In the second case a 42-year-old patient had a procedure of a biorevitalization with unstabilized hyaluronic acid complicated by the appearance of ecchymosis up to 12 mm in diameter and edema in the periorbital zone. A 0.05% aqueous solution of chlorhexidine bi-gluconate once per day and a multicomponent gel based on troxerutin, heparin sodium and dexpanthenol twice per day for seven days were prescribed as post-procedural rehabilitation. By the fourth day clinical improvement was noted. The edema disappeared, the color changed, the size of the ecchymosis decreased to 4 mm. The ecchymosis disappeared completely on the sixth day. In addition, the main characteristics of troxerutin, heparin sodium and depanthenol as components of a multicomponent gel were considered. A multicomponent gel based on troxerutin, heparin sodium and depanthenol as supportive aid helped to get complications completely cleaned out and significantly reduced the rehabilitation period for these patients. The authors consider it possible to recommend it as a means of post-procedural rehabilitation.

Identification of SARS-CoV-2 Receptor Binding Inhibitors by In Vitro Screening of Drug Libraries

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is responsible for the coronavirus disease 2019 (COVID-19) global pandemic. The first step of viral infection is cell attachment, which is mediated by the binding of the SARS-CoV-2 receptor binding domain (RBD), part of the virus spike protein, to human angiotensin-converting enzyme 2 (ACE2). Therefore, drug repurposing to discover RBD-ACE2 binding inhibitors may provide a rapid and safe approach for COVID-19 therapy. Here, we describe the development of an in vitro RBD-ACE2 binding assay and its application to identify inhibitors of the interaction of the SARS-CoV-2 RBD to ACE2 by the high-throughput screening of two compound libraries (LOPAC®1280 and DiscoveryProbeTM). Three compounds, heparin sodium, aurintricarboxylic acid (ATA), and ellagic acid, were found to exert an effective binding inhibition, with IC50 values ranging from 0.6 to 5.5 µg/mL. A plaque reduction assay in Vero E6 cells infected with a SARS-CoV-2 surrogate virus confirmed the inhibition efficacy of heparin sodium and ATA. Molecular docking analysis located potential binding sites of these compounds in the RBD. In light of these findings, the screening system described herein can be applied to other drug libraries to discover potent SARS-CoV-2 inhibitors.